small molecule. big impact.

toward safer IBD therapies

Treatment-associated side effects can have a significant impact on patient quality of life and treatment adherence. In the context of a life-long medical condition such as IBD, addressing potential tolerability issues becomes even more critical.

Mission

improve IBD drug tolerability

giiant pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision delivery remains a central focus for the development of new drug therapeutics, with limited systemic exposure for a safer profile while maximizing local action to improve IBD patient care.

more about us

Technology

orally-delivered | gut-restricted

giiant pharma‘s GastroIntestinal-Induced ANTi-inflammatory technology is a uniquely targeted delivery strategy, developed by two former Merck Frosst scientists, using the bacterial activity of the gut microbiota to bioactivate and release the active drug substance at specific locations in the lower GI tract.

more on technology

Although orally-delivered, giiant’s drug candidates are not systemically absorbed but remain able to achieve high drug concentrations in the colonic area.

Vision

high precision
colonic delivery

giiant pharma aims to become a GI leader in precision delivery technologies, with the ability to develop safer, patient-tailored drug therapeutics with local, tissue-specific delivery or bioactivation. These efforts should provide optimal treatment modalities to patients for various GI diseases and conditions.

more about us

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 Inflammatory bowel disease (IBD) represents a multi-billion dollar market opportunity with current therapies achieving a clinical remission rate of less than 20% on average   Carlsbad, CA – September 5, 2023 [...]

Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation

MONTREAL--(BUSINESS WIRE)--Giiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000. This financing will support the development of GT-2108, an orally administered, gut-restricted, colon-specific PDE4 (phosphodiesterase-4) inhibitor prodrug for [...]

Giiant Pharma Inc. appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry

MONTREAL–(BUSINESSWIRE)–Giiant Pharma Inc., a Montreal biotech company developing gut-restricted drug therapeutics at the pre-clinical stage in gastroenterology, announced the expansion of its research leadership team with the appointment of Christophe Mellon, PhD. Christophe’s rich and varied career path led him to leadership positions in pharmaceutical, biotech, and start-up companies for more than 20 years. Recently, [...]

Giiant Pharma Inc. extended its Seed round with AQC Capital and CQDM to ensure reaching clinical proof-of-concept

MONTREAL–(BUSINESSWIRE)– Giiant Pharma Inc. announced today that is closed an additional financing of $750,000 from AQC Capital (AQC) and $500,000 from CQDM for a total of $1.25 million. The preclinical-stage biotech Company’s recently closed a Seed round of $13.5 million, co-led by Amplitude Ventures and Genesys Capital and additional financing will support the development of [...]

Giiant Pharma Inc. strengthens its Board of Directors with the appointment of Dr. Marie Lindner

MONTREAL–(BUSINESSWIRE)–Giiant Pharma Inc., a preclinical-stage biotech company developing gut-restricted drug therapeutics in gastroenterology, announced the appointment of a seasoned executive as an independent board member. Dr. Marie Lindner worked in various executive roles in pharmaceutical, biotech, venture capital, start-up and medtech companies, spending over 30 years in multiple therapeutic areas, including gastroenterology. “I am thrilled [...]

Be a part of the revolution

careers